Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Single Ascending Dose Study of the Safety and Pharmacokinetics of TT30 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)

NCT01335165 is registered in ClinicalTrials.gov with Alexion Pharmaceuticals, Inc. as lead sponsor.

NCT NCT01335165
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01335165 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Single Ascending Dose Study of the Safety and Pharmacokinetics of TT30 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Lead sponsor
Alexion Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
April 30, 2011
Completion date
March 31, 2014
Enrollment
10 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

paroxysmal nocturnal hemoglobinuria (pnh)